| Lung Non-Small Cell Carcinoma14 |
|---|
| TMB High | Atezolizumab | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12587This retrospective study evaluated the clinical utility of blood tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab efficacy in advanced non-small cell lung cancer (NSCLC) who … (full text at CIViC) PMID 30082870 · Gandara et al., 2018 · Open in CIViC | civic |
| TMB High | Chemotherapy + ToripalimabCombination | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12798This is part of a multi-centred, randomised, placebo-controlled phase 3 trial, CHOICE-01, that examined therapeutic response to first-line chemotherapy plus PD-1 inhibitor in non-small cell lung cance… (full text at CIViC) PMID 39255777 · Xu et al., 2024 · Open in CIViC | civic |
| TMB High | Durvalumab + TremelimumabCombination | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID12799This is part of a open-label phase 3 trial, NEPTUNE, that examined therapeutic response to first-line durvalumab plus tremelimumab in patients with metastatic non-small cel lung cancer (NSCLC). 823 pa… (full text at CIViC) PMID 36240972 · de Castro et al., 2023 · Open in CIViC | civic |
| TMB High | Durvalumab/Tremelimumab Regimen | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID12760This exploratory analysis of the Phase 3 MYSTIC trial (NCT02453282) evaluated blood tumour mutational burden (bTMB) as a predictive biomarker for first-line durvalumab with or without tremelimumab vs … (full text at CIViC) PMID 32271377 · Rizvi et al., 2020 · Open in CIViC | civic |
| TMB High | Durvalumab/Tremelimumab Regimen | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID12822The MYSTIC study compared response rates for immunotherapy verses chemotherapy. Specifically looking at the efficacy of the anti-PD-L1 therapy, durvalumab, with/without the anti-CTLA-4 therapy, tremel… (full text at CIViC) PMID 33355200 · Si et al., 2021 · Open in CIViC | civic |
| TMB High | Immune Checkpoint Inhibitor | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID13061This retrospective study evaluated the predictive value of tumor mutational burden (TMB) for immune checkpoint inhibitor (ICI) outcomes in 97 patients with stage IV non-small cell lung cancer who had … (full text at CIViC) PMID 38950679 · Di Federico et al., 2024 · Open in CIViC | civic |
| TMB High | Immunotherapy | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13032A retrospective cohort study was performed with advanced NSCLC patients who had prior immunotherapy with available genomic testing, and TMB determined by NGS via the Foundation Medicine assay. 87 pati… (full text at CIViC) PMID 33972172 · Kao et al., 2021 · Open in CIViC | civic |
| TMB High | Ipilimumab/Nivolumab Regimen | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID12588This retrospective analysis assessed the association between tumor mutational burden (TMB) and the efficacy of nivolumab plus low-dose ipilimumab as first-line treatment for advanced/metastatic non-sm… (full text at CIViC) PMID 30785829 · Ready et al., 2019 · Open in CIViC | civic |
| TMB High | Ipilimumab/Nivolumab Regimen | Predictive | B | Supports Sensitivity Response | 4 | rejected | EID12612This part of the open-label multipart phase 3 trial, CheckMate 277 (Trial ID: 29658845), examined the performance of nivolumab plus ipilimumab compared to chemotherapy among non-small-cell lung cancer… (full text at CIViC) PMID 29658845 · Hellmann et al., 2018 · Open in CIViC | civic |
| TMB High | Ipilimumab/Nivolumab Regimen | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID13103Whole-exome sequencing-derived tumor mutational burden (TMB) was obtained from 75 patients recruited as part of the the CheckMate-012 trial (phase 1, open label, multicenter clincal trial of nivolumab… (full text at CIViC) PMID 29657128 · Hellmann et al., 2018 · Open in CIViC | civic |
| TMB High | Nivolumab | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12967In an exploratory analysis of the phase III CheckMate 026 trial in previously untreated stage IV or recurrent non-small-cell lung cancer, patients with high tumor mutational burden (≥243 missense muta… (full text at CIViC) PMID 28636851 · Carbone et al., 2017 · Open in CIViC | civic |
| TMB High | PD1 Inhibitor + PD-L1 InhibitorSubstitutes | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12586High Tumor Mutation Burden (TMB >19 mutations/Mb) represents a robust and platform-validated genomic biomarker predictive of clinical benefit from PD-1/PD-L1 immune checkpoint blockade in non–small ce… (full text at CIViC) PMID 35708671 · Ricciuti et al., 2022 · Open in CIViC | civic |
| TMB High | Pembrolizumab | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID12083Exomes were sequenced from two cohorts of non small cell lung cancer patients who were treated with pembrolizumab. In a discovery cohort of 16 patients, durable clinical benefit (DCB - partial or stab… (full text at CIViC) PMID 25765070 · Rizvi et al., 2015 · Open in CIViC | civic |
| TMB High | Pembrolizumab/Pemetrexed Regimen | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID12851This analysis of the Phase 2 KEYNOTE-782 trial (NCT03664024) evaluated the correlation of blood tumor mutational burden (bTMB) with the efficacy of first-line pembrolizumab plus platinum-based chemoth… (full text at CIViC) PMID 38422883 · Bar et al., 2024 · Open in CIViC | civic |